Early Trichoscopic Changes of Minoxidil Therapy in Male Pattern Hair Loss: A Prospective Cohort Study

Minoxidil 5% is a primary treatment for male pattern hair loss, but initial increased shedding can reduce compliance. While effective, early changes are not visible to the naked eye. Trichoscopy is a rapid, cost-effective tool for diagnosing hair disorders, yet no studies have examined its role in assessing early minoxidil effects. This study aims to evaluate trichoscopic changes in early minoxidil therapy to improve patient compliance.

A prospective cohort study was conducted from February 2019 to August 2020 at MGM Medical College and MY Hospital, Indore. Male patients with hair loss were evaluated using trichoscopy by a single observer. Other causes of hair loss were excluded.

Minor adverse effects were reported in 45.5% of subjects, with 20% experiencing scalp dryness, 11% increased shedding, and 14% both. Overall, 70% of patients were satisfied with minoxidil therapy. The mean hair loss duration was 13 months, and the most common presentation was N-H grade III. Family history was positive in 78 subjects.

Trichoscopy enhances early assessment of minoxidil therapy in male pattern hair loss, improving satisfaction and compliance. Positive changes can be observed within one month, encouraging continued treatment adherence.